156 related articles for article (PubMed ID: 9221613)
1. [Experimental methods in hepatology. Guidelines of the German Work Group for Study of the Liver. Therapy of ascites in liver diseases. German Work Group for Study of the Liver].
Gerbes AL
Z Gastroenterol; 1997 Apr; 35(4):295-300. PubMed ID: 9221613
[TBL] [Abstract][Full Text] [Related]
2. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
[TBL] [Abstract][Full Text] [Related]
3. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis.
Ginès P; Uriz J; Calahorra B; Garcia-Tsao G; Kamath PS; Del Arbol LR; Planas R; Bosch J; Arroyo V; Rodés J
Gastroenterology; 2002 Dec; 123(6):1839-47. PubMed ID: 12454841
[TBL] [Abstract][Full Text] [Related]
4. The patient with refractory ascites.
Gerbes AL
Best Pract Res Clin Gastroenterol; 2007; 21(3):551-60. PubMed ID: 17544117
[TBL] [Abstract][Full Text] [Related]
5. [Current ascites therapy].
Ochs A
Praxis (Bern 1994); 1997 Jan; 86(4):94-7. PubMed ID: 9064726
[TBL] [Abstract][Full Text] [Related]
6. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites.
Salerno F; Merli M; Riggio O; Cazzaniga M; Valeriano V; Pozzi M; Nicolini A; Salvatori F
Hepatology; 2004 Sep; 40(3):629-35. PubMed ID: 15349901
[TBL] [Abstract][Full Text] [Related]
7. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club.
Moore KP; Wong F; Gines P; Bernardi M; Ochs A; Salerno F; Angeli P; Porayko M; Moreau R; Garcia-Tsao G; Jimenez W; Planas R; Arroyo V
Hepatology; 2003 Jul; 38(1):258-66. PubMed ID: 12830009
[TBL] [Abstract][Full Text] [Related]
8. Pathogenetic factors and clinical elements in ascites and hepatorenal syndrome during liver cirrhosis.
Gentilini P; Laffi G; La Villa G; Raggi VC
Ann Ital Med Int; 1999; 14(4):264-84. PubMed ID: 10638019
[TBL] [Abstract][Full Text] [Related]
9. A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites.
Albillos A; Bañares R; González M; Catalina MV; Molinero LM
J Hepatol; 2005 Dec; 43(6):990-6. PubMed ID: 16139922
[TBL] [Abstract][Full Text] [Related]
10. Correlation between increased colloid osmotic pressure and the resolution of refractory ascites after transjugular intrahepatic portosystemic shunt.
Schiano TD; Black M; Hills C; Ter H; Bellary S; Miller LS
South Med J; 2000 Mar; 93(3):305-9. PubMed ID: 10728519
[TBL] [Abstract][Full Text] [Related]
11. Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites.
Deschênes M; Dufresne MP; Bui B; Fenyves D; Spahr L; Roy L; Lafortune M; Pomier-Layrargues G
Am J Gastroenterol; 1999 May; 94(5):1361-5. PubMed ID: 10235219
[TBL] [Abstract][Full Text] [Related]
12. Transjugular intrahepatic portosystemic shunt in the management of ascites and hepatorenal syndrome.
Senzolo M; Cholongitas E; Tibballs J; Burroughs A; Patch D
Eur J Gastroenterol Hepatol; 2006 Nov; 18(11):1143-50. PubMed ID: 17033432
[TBL] [Abstract][Full Text] [Related]
13. Ascites and spontaneous bacterial peritonitis: an Asian perspective.
Lee JM; Han KH; Ahn SH
J Gastroenterol Hepatol; 2009 Sep; 24(9):1494-503. PubMed ID: 19743995
[TBL] [Abstract][Full Text] [Related]
14. Management of ascites in patients with end-stage liver disease.
Saadeh S; Davis GL
Rev Gastroenterol Disord; 2004; 4(4):175-85. PubMed ID: 15580152
[TBL] [Abstract][Full Text] [Related]
15. Transjugular intrahepatic portosystemic shunts in hemodialysis-dependent patients and patients with advanced renal insufficiency: safety, caution, and encephalopathy.
Haskal ZJ; Radhakrishnan J
J Vasc Interv Radiol; 2008 Apr; 19(4):516-20. PubMed ID: 18375295
[TBL] [Abstract][Full Text] [Related]
16. Octreotide in the treatment of refractory ascites of cirrhosis.
Kalambokis G; Fotopoulos A; Economou M; Tsianos EV
Scand J Gastroenterol; 2006 Jan; 41(1):118-21. PubMed ID: 16373285
[TBL] [Abstract][Full Text] [Related]
17. [Ascites].
Volk BA
Schweiz Rundsch Med Prax; 1994 Sep; 83(38):1056-8. PubMed ID: 7939068
[TBL] [Abstract][Full Text] [Related]
18. The North American Study for the Treatment of Refractory Ascites.
Sanyal AJ; Genning C; Reddy KR; Wong F; Kowdley KV; Benner K; McCashland T;
Gastroenterology; 2003 Mar; 124(3):634-41. PubMed ID: 12612902
[TBL] [Abstract][Full Text] [Related]
19. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
Wong F; Pantea L; Sniderman K
Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
[TBL] [Abstract][Full Text] [Related]
20. Management of ascites in cirrhosis.
Sandhu BS; Sanyal AJ
Clin Liver Dis; 2005 Nov; 9(4):715-32, viii. PubMed ID: 16207572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
